Antimicrobial Agents and Chemotherapy, volume 60, issue 1, pages 6-13
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Laurent Detalle
1
,
Thomas Stöhr
1
,
Concepción Palomo
2
,
Pedro A. Piedra
3, 4
,
Brian E. Gilbert
3
,
Vicente Más
2
,
Andrena Millar
5
,
Ultan F Power
5
,
Catelijne Stortelers
1
,
Koen Allosery
1
,
Jose A. Melero
2
,
Erik Depla
1
1
Ablynx nv, Zwijnaarde, Belgium
|
2
Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
|
3
Publication type: Journal Article
Publication date: 2016-01-09
Q1
Q1
SJR: 1.357
CiteScore: 10.0
Impact factor: 4.1
ISSN: 00664804, 10986596
Pharmacology
Infectious Diseases
Pharmacology (medical)
Abstract
ABSTRACT
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.
Found
Found
Top-30
Journals
|
2
4
6
8
10
12
|
|
|
Frontiers in Immunology
11 publications, 4.8%
|
|
|
Scientific Reports
8 publications, 3.49%
|
|
|
Antimicrobial Agents and Chemotherapy
7 publications, 3.06%
|
|
|
Nature Communications
6 publications, 2.62%
|
|
|
Viruses
5 publications, 2.18%
|
|
|
International Journal of Molecular Sciences
5 publications, 2.18%
|
|
|
Journal of Virology
4 publications, 1.75%
|
|
|
Pharmacology and Therapeutics
4 publications, 1.75%
|
|
|
Frontiers in Microbiology
3 publications, 1.31%
|
|
|
Journal of Nanobiotechnology
3 publications, 1.31%
|
|
|
Expert Opinion on Pharmacotherapy
3 publications, 1.31%
|
|
|
International Journal of Biological Macromolecules
3 publications, 1.31%
|
|
|
Antiviral Research
3 publications, 1.31%
|
|
|
mAbs
3 publications, 1.31%
|
|
|
Science
3 publications, 1.31%
|
|
|
Antibodies
2 publications, 0.87%
|
|
|
Microorganisms
2 publications, 0.87%
|
|
|
Frontiers in Pharmacology
2 publications, 0.87%
|
|
|
Journal of Biological Chemistry
2 publications, 0.87%
|
|
|
Cell Reports
2 publications, 0.87%
|
|
|
iScience
2 publications, 0.87%
|
|
|
Advanced Drug Delivery Reviews
2 publications, 0.87%
|
|
|
Vaccine
2 publications, 0.87%
|
|
|
Drug Discovery Today
2 publications, 0.87%
|
|
|
Cell
2 publications, 0.87%
|
|
|
International Journal of Pharmaceutics
2 publications, 0.87%
|
|
|
Biochimica et Biophysica Acta - General Subjects
2 publications, 0.87%
|
|
|
Advanced Therapeutics
2 publications, 0.87%
|
|
|
Advances in Experimental Medicine and Biology
2 publications, 0.87%
|
|
|
2
4
6
8
10
12
|
Publishers
|
10
20
30
40
50
60
|
|
|
Elsevier
56 publications, 24.45%
|
|
|
Springer Nature
45 publications, 19.65%
|
|
|
Cold Spring Harbor Laboratory
20 publications, 8.73%
|
|
|
Taylor & Francis
19 publications, 8.3%
|
|
|
MDPI
19 publications, 8.3%
|
|
|
Frontiers Media S.A.
18 publications, 7.86%
|
|
|
American Society for Microbiology
12 publications, 5.24%
|
|
|
Wiley
8 publications, 3.49%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 1.75%
|
|
|
SAGE
2 publications, 0.87%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.87%
|
|
|
Oxford University Press
2 publications, 0.87%
|
|
|
American Physiological Society
2 publications, 0.87%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.87%
|
|
|
The American Association of Immunologists
1 publication, 0.44%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.44%
|
|
|
Microbiology Society
1 publication, 0.44%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.44%
|
|
|
American Chemical Society (ACS)
1 publication, 0.44%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.44%
|
|
|
Pleiades Publishing
1 publication, 0.44%
|
|
|
IntechOpen
1 publication, 0.44%
|
|
|
Publishing House OKI
1 publication, 0.44%
|
|
|
eLife Sciences Publications
1 publication, 0.44%
|
|
|
Annual Reviews
1 publication, 0.44%
|
|
|
Saint Petersburg Pasteur Institute
1 publication, 0.44%
|
|
|
Federal Medical Biological Agency
1 publication, 0.44%
|
|
|
Spandidos Publications
1 publication, 0.44%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.44%
|
|
|
10
20
30
40
50
60
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Detalle L. et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.
GOST all authors (up to 50)
Copy
Detalle L., Stöhr T., Palomo C., Piedra P. A., Gilbert B. E., Más V., Millar A., Power U. F., Stortelers C., Allosery K., Melero J. A., Depla E. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1128/aac.01802-15
UR - https://doi.org/10.1128/aac.01802-15
TI - Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
T2 - Antimicrobial Agents and Chemotherapy
AU - Detalle, Laurent
AU - Stöhr, Thomas
AU - Palomo, Concepción
AU - Piedra, Pedro A.
AU - Gilbert, Brian E.
AU - Más, Vicente
AU - Millar, Andrena
AU - Power, Ultan F
AU - Stortelers, Catelijne
AU - Allosery, Koen
AU - Melero, Jose A.
AU - Depla, Erik
PY - 2016
DA - 2016/01/09
PB - American Society for Microbiology
SP - 6-13
IS - 1
VL - 60
SN - 0066-4804
SN - 1098-6596
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2016_Detalle,
author = {Laurent Detalle and Thomas Stöhr and Concepción Palomo and Pedro A. Piedra and Brian E. Gilbert and Vicente Más and Andrena Millar and Ultan F Power and Catelijne Stortelers and Koen Allosery and Jose A. Melero and Erik Depla},
title = {Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2016},
volume = {60},
publisher = {American Society for Microbiology},
month = {jan},
url = {https://doi.org/10.1128/aac.01802-15},
number = {1},
pages = {6--13},
doi = {10.1128/aac.01802-15}
}
Cite this
MLA
Copy
Detalle, Laurent, et al. “Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 1, Jan. 2016, pp. 6-13. https://doi.org/10.1128/aac.01802-15.